Molbio Diagnostics Ltd

AI
Molbio Diagnosti Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Molbio Diagnostics Ltd

₹ 1,239 -1.64%
23 Oct - close price
molbiodiagnostics.com BSE: 544866 NSE: MOLBIO
About

Molbio Diagnostics is an innovative point-
of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases. Its flagship product, Truenat, is a portable, battery-powered PCR testing platform that delivers results within
an hour. Designed for use in resource-limited settings, it enables quick and decentralised disease diagnosis at the point of care.

Through its wholly owned subsidiary,
Bigtec Labs, Molbio has strong research
and development capabilities focused on creating diagnostic platforms for point-of-
care (POC) testing. From product development to large-scale deployment, the company aims
to improve access to reliable and affordable healthcare for everyone.[1]

[ add key points ]
Website BSE NSE
  • Market Cap ₹ 14,279 Cr.
  • Current Price ₹ 1,239
  • High / Low ₹ 1,687 / 926
  • Stock P/E 65.8
  • Book Value ₹
  • Dividend Yield 0.00 %
  • ROCE 18.0 %
  • ROE 13.8 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company's working capital requirements have reduced from 179 days to 143 days

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies

Part of Nifty IPO BSE IPO

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2025 Mar 2026 Jun 2026
95 439 399
105 332 308
Operating Profit -10 107 92
OPM % -10% 24% 23%
1 3 1
Interest 2 9 9
Depreciation 7 10 8
Profit before tax -17 91 76
Tax % -23% 28% 25%
-13 66 57
EPS in Rs -1.19 5.83 5.02
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1,271 776 327 756 971 1,313
676 457 286 552 746 1,061
Operating Profit 595 319 40 204 226 252
OPM % 47% 41% 12% 27% 23% 19%
1 5 8 -21 -2 4
Interest 35 25 6 8 9 23
Depreciation 12 42 19 24 26 36
Profit before tax 549 258 23 152 188 198
Tax % 25% 27% 32% 27% 26% 27%
410 187 16 111 140 145
EPS in Rs 40.58 16.64 1.38 9.88 12.40 12.83
Dividend Payout % 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 1%
3 Years: 59%
TTM: 35%
Compounded Profit Growth
10 Years: %
5 Years: -19%
3 Years: 111%
TTM: 1%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: 16%
3 Years: 15%
Last Year: 14%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 2 2 2 2 2 11
Reserves 333 681 737 848 988 1,123
257 105 57 70 26 346
215 85 123 157 291 260
Total Liabilities 806 874 920 1,077 1,307 1,741
55 182 189 209 215 257
CWIP 100 0 0 2 18 6
Investments 9 9 54 54 95 317
643 683 676 813 980 1,160
Total Assets 806 874 920 1,077 1,307 1,741

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
344 98 68 38 249 -38
-142 -87 -51 -31 -98 -256
-192 -20 31 -24 -17 292
Net Cash Flow 10 -9 48 -18 133 -2
Free Cash Flow 212 35 55 24 206 -74
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 78% 53% 251% 39% 139% 6%

Ratios

Standalone / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 61 113 194 174 86 100
Inventory Days 261 402 885 393 395 286
Days Payable 124 64 201 129 226 130
Cash Conversion Cycle 198 450 877 438 254 256
Working Capital Days 75 206 479 239 155 143
ROCE % 41% 4% 22% 21% 18%

Shareholding Pattern

Numbers in percentages

16 Recently
Sep 2026
41.29%
1.59%
19.09%
38.04%
No. of Shareholders 50,395

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.

DRHP

Concalls